NCT03653507 2026-04-17GLOWAstellas Pharma IncPhase 3 Active not recruiting507 enrolled 65 charts 2 FDA
NCT02465060 2026-04-13Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)National Cancer Institute (NCI)Phase 2 Active not recruiting6,452 enrolled 2 FDA
NCT03504397 2026-02-13SpotlightAstellas Pharma IncPhase 3 Active not recruiting565 enrolled 63 charts 2 FDA